COVID-19 Vaccines-Production Capacity & Development Timeline Market by Types (Virus-like Particle, Whole Virus, Protein, Antibodies, Viral Vector, and mRNA/DNA), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global COVID-19 vaccines-production capacity & development timeline market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. In early months of 2021, many companies had entered phase II trials of several vaccines across the globe and were ready to launch them for the public use. Rising investment from various research groups and their unparalleled research efforts with respect to scale and speed up the development of drugs are projected to expand the market. The COVID-19 vaccine development is growing faster than other vaccines development as other vaccines needed general time slot about 20 years. For instance, the development of Human Papilloma Virus (HPV) vaccine took about 26 years while the development of the Respiratory Syncytial Virus (RSV) vaccine took more than 50 years.
World Health Organization (WHO) and the government regulatory bodies had taken various initiatives for early research and vaccine development. The Coalition for Epidemic Preparedness Innovations (CEPI) and WHO have conducted the COVAX vaccine initiative for rapid development and rising access to contributing economy. These bodies also jointly working for enhancement of manufacturing capacity and proficient management of the buyer-supplier chain, to enable correct distribution of more than 2 billion doses by the end of 2021. Till August 2020, around 170 countries were present for the discussion of potential participation in COVAX.
As COVID-19 vaccine is considered to be a non-profit making market, therefore funding from governments is a major concern. Biomedical Advanced Research and Development Authority (BARDA) guided small companies for their benefits. BARDA helps in simplification of communication between regulatory agencies and provides guidance for trial design and expectations of regulatory agencies. Sanofi entered into a partnership with BARDA and GSK for its traditional vaccine, which was based on the further development of baculovirus expression system. Based on manufacturer’s and payer’s perspective, the Quality Adjusted Life Year (QALY) and Case Fatality Ratio (CFR) are also considered and vaccine pricing is set differently than other drugs pricing. The pricing depends on incidence of COVID-19, which motivate immunologists for rising focus on infection and development of exciting platforms.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing vaccine product supply to meet the enormous demand across the globe is one of the major factor responsible for driving the market growth.
- Rising government funding, increasing company investments, and quicker regulatory approvals are expected to fuel the market growth during the forecast period.
- Growing initiatives from regulatory bodies, arrival of next-generation vaccine platforms, and growing number of COVID-19 patients are anticipated to boost the market expansion in coming years.
- High cost operation related with R&D activities and long timeline for the development of therapeutic drugs and vaccines, required complex steps for the approval of every phase of clinical trials are estimated to impede the growth of the market.
- Stringent regulation and high cost associated with per dose vaccine are major factors to restrict the market growth during the forecast period.
Scope of the Report
The report on the global COVID-19 vaccines-production capacity & development timeline market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
COVID-19 Vaccines-Production Capacity & Development Timeline Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Types (Virus-like Particle, Whole Virus, Protein, Antibodies, Viral Vector, and mRNA/DNA) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Pfizer, Moderna, BioNtech, Sanofi, Zydus Cadila, CureVac, Imperial College London, Takara Bio, CanSino Biologics, Beth Israel Deaconess Medical Center, ReiThera, Novartis, Anhui Zhifei Longcom, Novavax, and the University of Queensland. |
Market Segment Insights
Protein segment is projected to hold a major market share
Based on types, the COVID-19 vaccines-production capacity & development timeline market is segmented into virus-like particle (VLP), whole virus, protein, antibodies, viral vector, and mRNA/DNA. The protein segment is expected to hold a key share of the market during the forecast period. This type of vaccine consists of purified pieces of pathogen to trigger the immune response. Owing to appearance of significant positive effects, the adoption of these vaccines are constantly increasing during the recent months.
On the other hand, the viral vector segment is anticipated to expand at a rapid pace during the forecast period owing to presence of manufacturing infrastructure that helps the development of effective vaccine in lesser time period. The whole virus type vaccine is used as deactivated and weakened pathogens, which triggers protective immunity. Inactivated pathogens are used by Sinopharm and Sinovac. The VLP vaccines consist of inactivated and weakened viruses. The protein-based vaccines are dominating the market for clinical trials. Many researchers and developers are focusing on evaluating and monitoring spike (S) protein.
North America is expected to dominate the market
On the basis of regions, the COVID-19 vaccines-production capacity & development timeline market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period owing to presence of multiple private organizations and academic institutes for developing vaccines. In the U.S., the Operation Warp Speed (OWS) is a key national program for various strategies related to vaccine development, therapeutics, and detection of coronavirus.
Segments
Segments Covered in the Report
The global COVID-19 vaccines-production capacity & development timeline market has been segmented on the basis of
Types
- Virus-like Particle
- Whole Virus
- Protein
- Antibodies
- Viral Vector
- mRNA/DNA
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer
- Moderna
- BioNtech
- Sanofi
- Zydus Cadila
- CureVac
- Imperial College London
- Takara Bio
- CanSino Biologics
- Beth Israel Deaconess Medical Center
- ReiThera
- Novartis
- Anhui Zhifei Longcom
- Novavax
- University of Queensland
Competitive Landscape
Key players competing in the COVID-19 vaccines-production capacity & development timeline market include Pfizer, Moderna, BioNtech, Sanofi, Zydus Cadila, CureVac, Imperial College London, Takara Bio, CanSino Biologics, Beth Israel Deaconess Medical Center, ReiThera, Novartis, Anhui Zhifei Longcom, Novavax, and the University of Queensland.
Many of these market players are looking at opportunities to implement business strategies such as mergers, acquisitions, partnerships, capacity expansion, and product launches to enhance their market shares. Companies are also adopting collaboration strategy for the best result and early launch of vaccines. For instance, Moderna collaborated with Lonza, AstraZeneca with Serum Institute of India and Pfizer, and BioNTech with Pfizer to expand their product portfolio.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. COVID-19 Vaccines-Production Capacity & Development Timeline Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. COVID-19 Vaccines-Production Capacity & Development Timeline Market - Supply Chain
4.5. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Forecast
4.5.1. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size (000’ Units) and Y-o-Y Growth
4.5.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Absolute $ Opportunity
5. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
5.3.1. Virus-like Particle
5.3.2. Whole Virus
5.3.3. Protein
5.3.4. Antibodies
5.3.5. Viral Vector
5.3.6. mRNA/DNA
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
7. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
7.4.1. Virus-like Particle
7.4.2. Whole Virus
7.4.3. Protein
7.4.4. Antibodies
7.4.5. Viral Vector
7.4.6. mRNA/DNA
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
8. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
8.4.1. Virus-like Particle
8.4.2. Whole Virus
8.4.3. Protein
8.4.4. Antibodies
8.4.5. Viral Vector
8.4.6. mRNA/DNA
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
9. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
9.4.1. Virus-like Particle
9.4.2. Whole Virus
9.4.3. Protein
9.4.4. Antibodies
9.4.5. Viral Vector
9.4.6. mRNA/DNA
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
10. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
10.4.1. Virus-like Particle
10.4.2. Whole Virus
10.4.3. Protein
10.4.4. Antibodies
10.4.5. Viral Vector
10.4.6. mRNA/DNA
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
11. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
11.4.1. Virus-like Particle
11.4.2. Whole Virus
11.4.3. Protein
11.4.4. Antibodies
11.4.5. Viral Vector
11.4.6. mRNA/DNA
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market: Market Share Analysis
12.2. COVID-19 Vaccines-Production Capacity & Development Timeline Distributors and Customers
12.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Pfizer
12.4.2. Moderna
12.4.3. BioNtech
12.4.4. Sanofi
12.4.5. Zydus Cadila
12.4.6. CureVac
12.4.7. Imperial College London
12.4.8. Takara Bio
2. Assumptions and Acronyms Used
3. Research Methodology
4. COVID-19 Vaccines-Production Capacity & Development Timeline Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. COVID-19 Vaccines-Production Capacity & Development Timeline Market - Supply Chain
4.5. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Forecast
4.5.1. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size (000’ Units) and Y-o-Y Growth
4.5.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Absolute $ Opportunity
5. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
5.3.1. Virus-like Particle
5.3.2. Whole Virus
5.3.3. Protein
5.3.4. Antibodies
5.3.5. Viral Vector
5.3.6. mRNA/DNA
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
7. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
7.4.1. Virus-like Particle
7.4.2. Whole Virus
7.4.3. Protein
7.4.4. Antibodies
7.4.5. Viral Vector
7.4.6. mRNA/DNA
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
8. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
8.4.1. Virus-like Particle
8.4.2. Whole Virus
8.4.3. Protein
8.4.4. Antibodies
8.4.5. Viral Vector
8.4.6. mRNA/DNA
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
9. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
9.4.1. Virus-like Particle
9.4.2. Whole Virus
9.4.3. Protein
9.4.4. Antibodies
9.4.5. Viral Vector
9.4.6. mRNA/DNA
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
10. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
10.4.1. Virus-like Particle
10.4.2. Whole Virus
10.4.3. Protein
10.4.4. Antibodies
10.4.5. Viral Vector
10.4.6. mRNA/DNA
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
11. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Market Size and Volume Forecast by Types
11.4.1. Virus-like Particle
11.4.2. Whole Virus
11.4.3. Protein
11.4.4. Antibodies
11.4.5. Viral Vector
11.4.6. mRNA/DNA
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa COVID-19 Vaccines-Production Capacity & Development Timeline Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global COVID-19 Vaccines-Production Capacity & Development Timeline Market: Market Share Analysis
12.2. COVID-19 Vaccines-Production Capacity & Development Timeline Distributors and Customers
12.3. COVID-19 Vaccines-Production Capacity & Development Timeline Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Pfizer
12.4.2. Moderna
12.4.3. BioNtech
12.4.4. Sanofi
12.4.5. Zydus Cadila
12.4.6. CureVac
12.4.7. Imperial College London
12.4.8. Takara Bio
Segments Covered in the Report
The global COVID-19 vaccines-production capacity & development timeline market has been segmented on the basis of
Types
- Virus-like Particle
- Whole Virus
- Protein
- Antibodies
- Viral Vector
- mRNA/DNA
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer
- Moderna
- BioNtech
- Sanofi
- Zydus Cadila
- CureVac
- Imperial College London
- Takara Bio
- CanSino Biologics
- Beth Israel Deaconess Medical Center
- ReiThera
- Novartis
- Anhui Zhifei Longcom
- Novavax
- University of Queensland
Key players competing in the COVID-19 vaccines-production capacity & development timeline market include Pfizer, Moderna, BioNtech, Sanofi, Zydus Cadila, CureVac, Imperial College London, Takara Bio, CanSino Biologics, Beth Israel Deaconess Medical Center, ReiThera, Novartis, Anhui Zhifei Longcom, Novavax, and the University of Queensland.
Many of these market players are looking at opportunities to implement business strategies such as mergers, acquisitions, partnerships, capacity expansion, and product launches to enhance their market shares. Companies are also adopting collaboration strategy for the best result and early launch of vaccines. For instance, Moderna collaborated with Lonza, AstraZeneca with Serum Institute of India and Pfizer, and BioNTech with Pfizer to expand their product portfolio.
Our Clients
Related Reports
Some other reports from this category!
